Key result
VASP knockout in rats fails to alter platelet aggregation, thrombogenesis, or prasugrel efficacy.
Why the study?
Does VASP knockout affect platelet aggregation, thrombogenesis, haemostasis, or the antiplatelet effect of prasugrel in rats?
Does VASP knockout affect platelet aggregation, thrombogenesis, haemostasis, or the antiplatelet effect of prasugrel in rats?
VASP is not a major mediator of platelet aggregation, thrombogenesis, haemostasis, or the antiplatelet effect of prasugrel in rats, despite phosphorylated VASP being a surrogate marker for P2Y12 antagonists.
Answers are grounded in this paper and cite their sources.
Challenges VASP as essential for rat platelet aggregation; leaves open its relevance to human thrombosis or prasugrel response.
Vasodilator-stimulated phosphoprotein (VASP) is a member of actin regulatory proteins implicated in platelet adhesion. In addition, phosphorylation of VASP is utilised for the assessment of platelet reactivity in patients treated with P2Y12 receptor antagonists, a class of antiplatelet agents. However, the role of VASP in platelet aggregation, thrombogenesis, haemostasis, and the antiplatelet effect of P2Y12 receptor antagonists remains unclear. We investigated these effects using heterozygous and homozygous VASP knockout rats generated with a CRISPR/Cas9 system. Baseline characteristics, such as haematology and other biochemical parameters, were comparable among the genotypes. In vitro platelet aggregation stimulated by adenosine diphosphate (ADP) or collagen, P-selectin expression of rat platelets treated with ADP, and in vivo thrombocytopenia induced by collagen were also comparable among the genotypes. In addition, in vivo thrombogenesis in a ferric chloride-induced arterial thrombosis model and bleeding time were also comparable among the genotypes. Furthermore, the in vitro antiplatelet effect of prasugrel, a third-generation P2Y12 receptor antagonist, was unaffected by VASP knockout. Although phosphorylated VASP is still an important surrogate marker specific for P2Y12 antagonists, our findings demonstrate that VASP is not a major mediator of platelet aggregation, thrombogenesis, haemostasis, and the antiplatelet effect of prasugrel in rats.
No takes yet. Share an insight, caveat, or question.
Ito et al. (2018) studied Thrombosis and haemostasis. VASP knockout vs. Wild-type rats was evaluated on Platelet aggregation, thrombogenesis (time to occlusion), and bleeding time. VASP knockout in rats did not significantly alter ADP- or collagen-induced platelet aggregation, thrombogenesis, haemostasis, or the antiplatelet effect of prasugrel.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: